Proteomic profiling differentiates lymphoma patients with and without concurrent myeloproliferative neoplasia

Johanne Marie Holst, Marie Beck Enemark, Martin Bjerregaard Pedersen, Kristina Lystlund Lauridsen, Trine Engelbrecht Hybel, Michael Roost Clausen, Henrik Frederiksen, Michael Boe Møller, Peter Nørgaard, Trine Lindhardt Plesner, Stephen Jacques Hamilton-Dutoit, Francesco D’amore, Bent Honoré, Maja Ludvigsen*

*Corresponding author af dette arbejde
2 Citationer (Scopus)


Myeloproliferative neoplasia (MPN) and lymphoma are regarded as distinct diseases with different pathogeneses. However, patients that are diagnosed with both malignancies occur more frequently in the population than expected. This has led to the hypothesis that the two malignancies may, in some cases, be pathogenetically related. Using a mass spectrometry-based proteomic approach, we show that pre-treatment lymphoma samples from patients with both MPN and lym-phoma, either angioimmunoblastic T-cell lymphoma (MPN-AITL) or diffuse large B-cell lymphoma (MPN-DLBCL), show differences in protein expression compared with reference AITL or DLBCL samples from patients without MPN. A distinct clustering of samples from patients with and without MPN was evident for both AITL and DLBCL. Regarding MPN-AITL, a pathway analysis revealed disturbances of cellular respiration as well as oxidative metabolism, and an immunohistochemical evaluation further demonstrated the differential expression of citrate synthase and DNAJA2 protein (p = 0.007 and p = 0.015). Interestingly, IDH2 protein also showed differential expression in the MPN-AITL patients, which contributes to the growing evidence of this protein’s role in both myeloid neoplasia and AITL. In MPN-DLBCL, the disturbed pathways included a significant downregulation of protein synthesis as well as a perturbation of signal transduction. These results imply an underly-ing disturbance of tumor molecular biology, and in turn an alternative pathogenesis for tumors in these patients with both myeloid and lymphoid malignancies.

Udgave nummer21
StatusUdgivet - 1 nov. 2021


Dyk ned i forskningsemnerne om 'Proteomic profiling differentiates lymphoma patients with and without concurrent myeloproliferative neoplasia'. Sammen danner de et unikt fingeraftryk.